Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Lalit Raut"'
Publikováno v:
South Asian Journal of Cancer, Vol 2, Iss 4, Pp 260-264 (2013)
Context: Chronic Myeloid Leukemia (CML) constitutes around 3% of leukemia in the children and adolescent age group. Aims: The aim of the study was to evaluate the characteristics at presentation and the treatment outcome of CML in the children and ad
Externí odkaz:
https://doaj.org/article/b0af15f7496c4b67a43fd7ac081b7fc8
Publikováno v:
International Journal of Hematology-Oncology and Stem Cell Research, Vol 6, Iss 2, Pp 29-31 (2012)
The most frequently studied association between a hepatitis virus and Non Hodgkin lymphoma (NHL) has been with hepatitis C virus (HCV). Association with Hepatitis B virus (HBV) is less studied. In this regard mixed cryoglobulinemia (MC) is more commo
Externí odkaz:
https://doaj.org/article/1cfeb39e28984468849aabed1e550cc4
Publikováno v:
International Journal of Hematology-Oncology and Stem Cell Research, Vol 6, Iss 2 (2012)
The most frequently studied association between a hepatitis virus and Non Hodgkin lymphoma (NHL) has been with hepatitis C virus (HCV). Association with Hepatitis B virus (HBV) is less studied. In this regard mixed cryoglobulinemia (MC) is more commo
Externí odkaz:
https://doaj.org/article/a2822420d1304ec89aeb0f2a94ae2e2c
Publikováno v:
Cureus.
Publikováno v:
2016 IEEE Conference on Antenna Measurements & Applications (CAMA).
It was observed that movement tracking applications of a RFID are not cost effective due to the fact that it requires large system configuration consisting of three or more RFID readers. In this paper we introduced a new technique, which uses antenna
Autor:
Lalit Raut
Publikováno v:
Cancer Research Journal. 2:70
Different clinical conditions of immunodeficiency and leukemic transformation were described recently. These are being associated with GATA-2 mutations. This is emerging as a new and interesting syndrome. This is a review of this condition.
Autor:
Lalit Raut
Publikováno v:
Blood research
TO THE EDITOR: Firstly, I congratulate Chul Won Jung for the perspectives on the role of JAK1/2 inhibitors in the management of primary myelofibrosis (PMF) [1]. I would like to share some of my thoughts on the same topic. In comparison with conventio